Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Dec;47(12):1436-1438.
doi: 10.1111/1346-8138.15577. Epub 2020 Aug 29.

Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin

Rui Sasaki  1 , Taku Fujimura  1 , Chunbing Lyu  1 , Setsuya Aiba  1
Affiliations
Case Reports

Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin

Rui Sasaki et al. J Dermatol. 2020 Dec.

Abstract

Enfortumab vedotin (EV) is a novel, fully humanized monoclonal antibody-drug conjugate composed of an anti-Nectin-4 antibody joined to monomethyl auristatin E. In this report, we described a case of a severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing in patients with metastatic urothelial cancer treated with EV. Because phase II and phase III clinical studies are ongoing, in the future, substantial amounts of EV are expected to be used for the treatment of metastatic urothelial cancer. Therefore, understanding the mechanisms of drug eruption caused by EV is important for oncologists as well as dermatologists.

Keywords: enfortumab vedotin; full-thickness epidermal necrosis; molecular-targeted therapy; severe drug eruption; tumor-infiltrating leukocytes.

PubMed Disclaimer

References

    1. Rosenberg J, Sridhar SS, Zhang J et al. EV-101: a Phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol 2020; 38: 1041-1049.
    1. Uhlén M, Fagerberg L, Hallström BM et al. Proteomics. Tissue-based map of the human proteome. Science 2015; 347: 1260419.
    1. Wu S, Adamson AS. Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma. Dermatol Online J 2019; 25: 13030/qt4j44w7w6.
    1. Mollo MR, Antonini D, Mitchell K et al. p63-dependent and independent mechanisms of nectin-1 and nectin-4 regulation in the epidermis. Exp Dermatol 2015; 24: 114-119.
    1. Fortugno P, Josselin E, Tsiakas K et al. Nectin-4 mutations causing ectodermal dysplasia with syndactyly perturb the rac1 pathway and the kinetics of adherens junction formation. J Invest Dermatol 2014; 134: 2146-2153.

Publication types

LinkOut - more resources